What Is BMY Fair Value?
Bristol-Myers Squibb Company (BMY) fair value estimate using multiple valuation models, updated daily.
As of September 15, 2026, Bristol-Myers Squibb Company (BMY) has a composite fair value estimate of $88.84 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $63.73, suggesting the stock is undervalued by 39.4%.
Data as of September 15, 2026 (today)
Composite Fair Value
Undervalued4 of 4 models$88.84
vs. current price of $63.73(+39.4%)
How Is BMY Fair Value Calculated?
Four independent models estimate what BMY is worth. Each uses different inputs and assumptions. The composite blends them by weight.
BMY Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$123.50
+93.8%Undervalued
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$68.57
+7.6%Fair Value
Inputs used
BMY Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$41.33
-35.1%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$69.49
+9.0%Fair Value
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $63.73 is 93.8% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $8.41B | $7.99B |
| Year 2 | $8.72B | $7.87B |
| Year 3 | $9.04B | $7.75B |
| Year 4 | $9.38B | $7.63B |
| Year 5 | $9.72B | $7.52B |
| Year 6 | $10.08B | $7.40B |
| Year 7 | $10.45B | $7.29B |
| Year 8 | $10.84B | $7.18B |
| Year 9 | $11.24B | $7.07B |
| Year 10 | $11.65B | $6.96B |
| Terminal Value | $428.69B | $256.11B |
What Are BMY's Key Financial Metrics?
Earnings & Growth
Current Price
$63.73
EPS (TTM)
$4.54
Forward P/E
9.7
Profit Margin
18.9%
Cash & Balance Sheet
Free Cash Flow
8.1B
EBITDA
18.9B
Book Value
$10.93
Total Debt
45.1B
What Do Analysts Say About BMY?
Low
$40.00
Average
$66.42
High
$80.00
Upside
+4.2%
BMY Fair Value FAQ
What is the fair value of BMY?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), BMY's estimated fair value is $88.84. The stock is currently trading at $63.73, which makes it undervalued by our analysis.
How is BMY's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is BMY overvalued or undervalued?
Based on our analysis, BMY is undervalued. The current price of $63.73 is 39.4% below our estimated fair value of $88.84.
What do Wall Street analysts say about BMY?
24 analysts cover Bristol-Myers Squibb Company with a consensus rating of "Buy." The average price target is $66.42, ranging from $40.00 to $80.00. This implies 4.2% upside from the current price.